Generated by AI
TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T cell receptor-engineered T cell therapies for cancer. The company’s current work centers on TCR-T programs designed to address hematologic malignancies and solid tumors, with lead candidates aimed at eliminating residual disease and reducing relapse risk after allogeneic hematopoietic cell transplantation. TScan Therapeutics also advances multiplexed TCR-T approaches for solid tumors and uses its platform to identify shared tumor antigens and evaluate off-target TCR interactions, supporting the selection of more precise therapeutic targets. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics operates in the immuno-oncology and cell therapy segments of biotechnology, where its pipeline reflects a focus on targeted, personalized cancer treatment development.
Website830 Winter Street
Waltham, MA, 02451
United States
The latest articles about TCRX.
Announced strategic reorganization to focus on in vivo-engineered TCR-T cell therapy for solid tumors Advancing PRAME- and MAGE-A4-targeted in vivo TCR-T candidates for solid tumors through IND-enabling studies; on track to dose first patient in Q4 2027 Paused further enrollment in Phase 3 ALLOHA-2™ study of TSC-101; allowing data to mature and actively seeking strategic partners Cash and cash equivalents fund operations into the fourth quarter of 2027 WALTHAM, Mass., Nov. 12, 2026 (GLOBE NEWSWI
Detailed price information for Tscan Therapeutics Inc (TCRX-Q) from The Globe and Mail including charting and trades.
Summary of Sep 2's posts. Generated by AI.
Summary of Nov 3's posts. Generated by AI.
Summary of Sep 2's posts. Generated by AI.
Investors talking about TCRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.